Epcoritamab Chemical Properties

form 

Liquid

color 

Colorless to light yellow

Epcoritamab Usage And Synthesis

Uses

Epcoritamab (GEN3013) is an bispecific IgG1 antibody redirecting T-cells toward CD3×CD20+ tumor cells. Epcoritamab induces potent T-cell-mediated cytotoxicity towards B-cell NHL cell lines[1].

References

[1] van der Horst HJ, et al. Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment. Blood Cancer J. 2021 Feb 18;11(2):38. DOI:10.1038/s41408-021-00430-6
[2] Thieblemont C, et al. Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial. J Clin Oncol. 2023 Apr 20;41(12):2238-2247. DOI:10.1200/JCO.22.01725

Epcoritamab(2134641-34-0)Related Product Information

• Relfovetmab
• Tavolimab
• Dovanvetmab
• Atidortoxumab
• Votumumab
• Lulizumab Pegol
• Xeligekimab
• Bapotulimab
• Mitumomab
• Immunoglobulin G2/G4, anti-(human complement C5) (human-Mus musculus ALXN1210 heavy chain), disulfide with human-Mus musculus ALXN1210 κ-chain, dimer